Literature DB >> 9144742

Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver.

A Nolting1, R K DeLong, M H Fisher, E Wickstrom, G M Pollack, R L Juliano, K L Brouwer.   

Abstract

PURPOSE: This study was conducted to investigate the impact of backbone modifications on the hepatobiliary disposition of oligonucleotides.
METHODS: The disposition of backbone-modified antisense oligonucleotides [phosphorothioate (PS) and methylphosphonate (MP)] of the same base-length and sequence (5'-TAC-GCC-AAC-AGC-TCC-3'), complementary to the codon 12 activating mutation of Ki-ras, was investigated in the isolated perfused rat liver. Livers were perfused for 2 hr: perfusate and bile concentrations were analyzed by HPLC. Hepatocellular distribution was examined by measuring the amount of radiolabeled PS oligonucleotide associated with hepatocytes and Kupffer cells. Protein binding of the PS and MP oligonucleotides was determined in rat serum by ultrafiltration.
RESULTS: MP oligonucleotide perfusate concentrations remained constant during the 2-hour perfusion. In contrast, PS oligonucleotide was eliminated slowly by the isolated perfused liver [CI = 1.05 +/- 0.21 mL/min; extraction ratio = 0.06 +/- 0.01]. Uptake of PS oligonucleotide by Kupffer cells appeared to exceed uptake by hepatocytes, based on standard cell separation techniques as well as confocal microscopy. The degree of protein binding in rat serum was greater for the PS oligonucleotide (79.9 +/- 2.2%) than for the MP oligonucleotide (53.0 +/- 4.7%).
CONCLUSIONS: Backbone modifications significantly-influence the hepatic clearance of oligonucleotides. Uncharged MP oligonucleotides are not extracted by the isolated perfused rat liver, whereas the charged PS oligonucleotide is processed more readily.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144742     DOI: 10.1023/a:1012116003706

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

Review 1.  Therapeutic applications of oligonucleotides.

Authors:  S T Crooke
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

Review 2.  Oligonucleotides as therapeutic agents.

Authors:  J S Cohen
Journal:  Pharmacol Ther       Date:  1991-11       Impact factor: 12.310

3.  A simple and inexpensive membrane "lung" for small organ perfusion.

Authors:  R L Hamilton; M N Berry; M C Williams; E M Severinghaus
Journal:  J Lipid Res       Date:  1974-03       Impact factor: 5.922

4.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.

Authors:  H Sands; L J Gorey-Feret; A J Cocuzza; F W Hobbs; D Chidester; G L Trainor
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

6.  Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

Authors:  P A Cossum; H Sasmor; D Dellinger; L Truong; L Cummins; S R Owens; P M Markham; J P Shea; S Crooke
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

7.  In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.

Authors:  R Zhang; Z Lu; X Zhang; H Zhao; R B Diasio; T Liu; Z Jiang; S Agrawal
Journal:  Clin Chem       Date:  1995-06       Impact factor: 8.327

8.  Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs.

Authors:  J A Hughes; A V Avrutskaya; K L Brouwer; E Wickstrom; R L Juliano
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

9.  In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides.

Authors:  J G Zendegui; K M Vasquez; J H Tinsley; D J Kessler; M E Hogan
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

10.  Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.

Authors:  R Zhang; J Yan; H K Shahinian; H Shahinian; G Amin; Z Lu; T Liu; M S Saag; Z Jiang; J Temsamani; R R Martin
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

View more
  3 in total

Review 1.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation.

Authors:  M K Bijsterbosch; E T Rump; R L De Vrueh; R Dorland; R van Veghel; K L Tivel; E A Biessen; T J van Berkel; M Manoharan
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

3.  Simultaneous Targeting of Multiple oncomiRs with Phosphorothioate or PNA-Based Anti-miRs in Lymphoma Cell Lines.

Authors:  Karishma Dhuri; Sai Pallavi Pradeep; Jason Shi; Eleni Anastasiadou; Frank J Slack; Anisha Gupta; Xiao-Bo Zhong; Raman Bahal
Journal:  Pharm Res       Date:  2022-09-07       Impact factor: 4.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.